Dr. Rachel Carmody is the Thomas D. Cabot Associate Professor of Human Evolutionary Biology at Harvard University, affiliated with the Faculty of Arts and Sciences. Her research focuses on energy metabolism, gut microbiome interactions, and their evolutionary implications. She leads the Nutritional & Microbial Ecology Lab, exploring how diet, genetics, and microbial communities influence human energy dynamics. Her work integrates evolutionary biology, physiology, and metagenomics to address questions about human uniqueness in digestion, maternal-offspring energy conflicts, and non-caloric dietary components. Office: Museum of Comparative Zoology 542; Email: carmody@fas.harvard.edu. Key research themes include gut microbiome-modulated obesity, placental hormone roles in pregnancy metabolism, and dietary digestibility frameworks. She also investigates evolutionary shifts in gut microbiota during human industrialization and animal domestication. Her lab employs mouse models, comparative studies, and multiomics approaches to dissect host-microbial interactions. Recent articles highlight microbiome effects on exercise-induced weight changes, antibiotic-induced obesity mechanisms, and cross-cultural dietary comparisons. While no awards are explicitly listed, her prolific publications reflect sustained impact in nutritional and evolutionary microbiology. No student advisees or grants are detailed in the provided text.
Jethro Johnson is an Innovation Track Principal Investigator at the Kennedy Institute of Rheumatology and Deputy Director of the Oxford Centre for Microbiome Studies (OCMS) at the University of Oxford. His work integrates computational genomics and microbiome research to explore host-microbiome interactions in health and disease. PhD in Nutritional Ecology (University of Auckland, 2012) MRC Career Development Fellowship Former postdoctoral researcher at Jackson Laboratory for Genomic Medicine Research focuses on: Mechanistic understanding of gut microbiome impacts on metabolic diseases Multi-omic data integration for host-microbiome studies Computational approaches to microbiome analysis Methodological developments in 16S rRNA gene profiling Publications emphasize microbiome-disease associations, methodological innovations, and computational genomics applications across human and mouse models. Key themes include metabolic dysfunction, immune interactions, and microbial diversity analysis. Scientific recognition includes: MRC Career Development Fellowship in Computational Genomics As OCMS Deputy Director, he contributes to advancing microbiome research infrastructure and collaborative projects while leading his own computational genomics group at the Kennedy Institute.
Dr. Asma Zaidi is a Professor of Biochemistry at Kansas City University specializing in Parkinson's disease research. Her work investigates the role of plasma membrane Ca2+-ATPase (PMCA) in dopaminergic neuron degeneration. Using human postmortem tissue, cell cultures, and mouse models, her research demonstrates how aging and neurotoxins reduce PMCA function in the substantia nigra, leading to selective neuronal death in Parkinson's. Her findings identify potential therapeutic targets for neuroprotection.
Bruce Clurman, MD, PhD, serves as Executive Vice President, Chief Scientific Officer, and Deputy Director of Fred Hutchinson Cancer Center. He holds the Rosput Reynolds Endowed Chair and is a Professor in both the Translational Science and Therapeutics Division and Human Biology Division at Fred Hutch, with additional appointments as Professor in the University of Washington Department of Medicine and Adjunct Professor in Pathology. His educational background includes: BA in Philosophy, University of Virginia (1981) PhD in Viral Oncology, Cornell University Graduate School of Medical Sciences (1988) MD, Cornell University Medical College (1989) Residency at Brigham and Women’s Hospital, Boston Fellowship in Medical Oncology/Molecular Medicine at Fred Hutch and UW Dr. Clurman's research centers on cell cycle regulation and protein degradation mechanisms in cancer development. His lab investigates how ubiquitin-proteasome system dysregulation—particularly involving Fbw7 tumor suppressor, cyclin E, CDK2, and Wee1 kinases—drives oncogenesis. Current work focuses on exploiting DNA replication stress and mutations in cell cycle regulators to develop targeted therapies that selectively kill cancer cells while sparing healthy tissue. His major scientific recognitions include: W. M. Keck Foundation Distinguished Young Scholar (1999) National Cancer Institute Clinical Investigator Award José Carreras Fellowship James S. McDonnell Foundation Scholarship Election to American Society for Clinical Investigation (2005) As leader of the Clurman Lab, he directs multidisciplinary research integrating biochemistry, proteomics, and genetically engineered mouse models. He actively contributes to Fred Hutch's Immunotherapy, Pathogen-Associated Malignancies, and Translational Data Science Integrated Research Centers while maintaining clinical practice in blood cancer transplantation.
Istvan Mody is a Professor at the University of California, Los Angeles (UCLA) with appointments in the Department of Neurology and Department of Physiology . His research focuses on synaptic signaling in health and disease, including mechanisms of GABAergic transmission, calcium homeostasis, and their roles in neurological disorders such as epilepsy, Alzheimer's disease, Huntington's disease, stress, alcoholism, and postpartum depression. He utilizes advanced techniques like patch-clamp electrophysiology, neuroanatomical and immunohistochemical methods, and molecular biology in animal models and human brain tissue . Research Interests: Dr. Mody investigates the physiology, pharmacology, and pathology of synaptic transmission and extrasynaptic receptor activation , with a particular emphasis on GABA(A) receptors and their subunit-specific modulation. His work explores how disruptions in excitation-inhibition balance contribute to neurological diseases, including mechanisms of tonic inhibition , calcium signaling , and neurosteroid interactions . He also studies the effects of chronic stress and hormonal fluctuations on neural excitability and behavior. Publications Trends: Recent studies highlight his work on gamma oscillations in Alzheimer's models, microglial dynamics , and rehabilitation strategies for stroke. His lab develops optical tools like dqGEVI for neuronal activity monitoring and investigates human brain organoids to model network dysfunction in epilepsy and intellectual disability. Laboratory Location: 635 Charles Young Dr S, Los Angeles, CA 90095, United States.
Prof. Ilse Dewachter is the head of the Biomed Neuroscience research group at Hasselt University (UHasselt), specializing in Alzheimer’s therapy and prevention for over 25 years. Her work focuses on multi-targeted therapies targeting tau, inflammation, and ApoE, alongside pioneering research into disease prevention via blood-based biomarkers. Recent studies explore a protective APOE3ch mutation that halted Alzheimer’s progression in a patient, offering hope for new treatments. Research Interests: - Alzheimer’s disease mechanisms (Abeta, tau, inflammation) - Multi-target therapies and biomarker development - Neurodegenerative disease prevention strategies - Genetic mutations impacting disease progression Articles Overview: Her most recent work (2025-2022) addresses neuroinflammation, tau propagation models, and AI-driven neuroimaging. Key themes include APOE genetics, blood-brain barrier dynamics, and exercise impacts on cognition. Funding & Grants: Current projects require significant investment for advanced biomarker equipment and clinical trials. A notable €300,000 grant funded research on brain lipid metabolism’s role in Alzheimer’s. Labs & Teams: Leads the BIOMED Neuroscience group at UHasselt, collaborating internationally on preclinical models and drug development.
Jeremy Wang, PhD is an Assistant Professor in the Department of Genetics at the UNC School of Medicine . His research focuses on applying high-performance computational methods and machine learning to analyze high-throughput sequence data using long-read technologies (e.g., Oxford Nanopore) to advance precision personalized medicine . Key disease areas include Inflammatory Bowel Diseases (IBD) Respiratory Infectious Diseases His lab specializes in microbiome analysis , host-pathogen interactions , and computational genomics , working with collaborators in clinical, translational, and computational domains. His publications demonstrate expertise in long-read sequencing applications for Pediatric cancer classification SARS-CoV-2 genomic epidemiology Microbiome spatiotemporal dynamics Murine disease models Drosophilid genome assemblies Metagenomic bias analysis Collaborations span UNC and global institutions, with current work extending to clinical laboratory partnerships for pathogen sequencing and oral microbiome sampling methodology.
Pedro A Hermida de Viveiros, MD serves as an Assistant Professor in the Department of Medicine, Division of Hematology and Oncology at Northwestern University's Feinberg School of Medicine. His clinical practice focuses on solid tumor oncology with specialized expertise in sarcomas and precision medicine approaches. His research interests center on clinical development of novel therapeutic strategies for sarcomas and gastrointestinal stromal tumors (GIST), emphasizing biomarker-driven treatments and molecularly targeted therapies. Key areas include IDH1-mutant chondrosarcoma management, neoadjuvant response assessment in sarcomas, and immunotherapy-radiotherapy combinations for metastatic disease. Analysis of his recent publications reveals a consistent focus on translating molecular targets into clinical applications, particularly through phase 1-3 trials of targeted agents like ivosidenib and IDRX-42. His work bridges radiological assessment, pathological response, and precision oncology frameworks for rare solid tumors. Professional engagements include active membership in major oncology societies: American Society of Clinical Oncology (ASCO) Connective Tissue Oncology Society (CTOS) Sociedade Brasileira de Oncologia Clínica (SBOC) European Society for Medical Oncology (ESMO) He currently leads four active clinical trials through the Robert H. Lurie Comprehensive Cancer Center, including the CHONQUER phase 3 study of ivosidenib for IDH1-mutant chondrosarcoma and first-in-human trials of novel agents for advanced solid tumors and GIST. His work integrates translational research with clinical trial design to advance personalized treatment paradigms.
Xenophon Papademetris is a Professor of Biomedical Informatics & Data Science and Radiology & Biomedical Imaging at Yale School of Medicine. He serves as Associate Director of Biomedical Imaging Data Sciences at Yale Biomedical Imaging Institute and directs the Medical Software and Medical Artificial Intelligence Certificate Program. PhD in Electrical and Information Sciences from Yale University (2000) BA from Cambridge University (1994) Postdoctoral Fellowship at Yale University (2002) His research focuses on medical image analysis, machine learning, and biomedical software development. He has developed tools like BioImage Suite Web and contributed to standards committees at the Association for the Advancement of Medical Instrumentation (AAMI). His work spans modalities including MRI, CT, PET, and optical imaging. Recent publications emphasize neuroimaging analysis, explainable AI in healthcare, and multimodal data integration across species. He leads NIH-funded research under the BRAIN Initiative (R24 MH114805) and has authored a textbook on Medical Software published by Cambridge University Press. IEEE Senior Member Yale Brown-Coxe Postdoctoral Fellowship Harding Bliss Prize for Excellence in Engineering He directs the BioImage Suite Project, creating web-based image analysis tools using JavaScript and WebAssembly. His teaching includes both academic courses and a Coursera program on Medical Software with over 14,000 enrollments.
Professor Mirko Trajkovski leads the Laboratory of Metabolic Diseases at the Faculty of Medicine, University of Geneva. He completed his PhD at the International Max Planck School in Dresden (2005), followed by postdoctoral research at ETH Zurich, before establishing his lab at University College London (2012) and moving to Geneva (2013). His work focuses on adipose tissue plasticity , gut microbiota , and their roles in obesity , diabetes , and insulin resistance . Swiss National Science Foundation Professor (2014) ERC Starting Grant (2014) & Consolidator Grant (2019) Dr Walter Seipp Prize & Carl Gustav Carus Prize (2005) His lab investigates fat browning mechanisms , microbiota-host communication , and multi-tissue metabolic regulation using in vivo , in vitro , and human cohort approaches. Recent publications emphasize microbiome-based therapies , temperature effects on metabolism , and gut-bone-adipose crosstalk . Current advisees include PhD student Silas Kieser, with past members like Jing Xue, Salvatore Fabbiano, and Claire Chevalier contributing to immuno-metabolism and microbial engineering projects.
Prof. Dr. Dr. Elisabeth Binder is the Director of the Max Planck Institute of Psychiatry and leads the Max Planck Research Group "Genes and Environment" in Munich, Germany. Her research focuses on molecular mechanisms underlying psychiatric disorders, particularly how genetic and environmental factors interact in disease development. Education: Medicine (University of Vienna), Neuroscience (Emory University) Affiliations: Max Planck Institute of Psychiatry, International Max-Planck Research School Translational Psychiatry, Graduate School of Systemic Neuroscience Research Interests: Elisabeth Binder investigates gene-environment interactions in psychiatric disorders, emphasizing early trauma and stress response. Her work employs next-generation sequencing, epigenetic analysis, and induced pluripotent stem cells to identify biological markers for disease prevention and treatment. Scientific Awards: Theodore Reich Young Investigator Award (2010) Max Hamilton Memorial Prize (2012) Eva King-Killam Research Award (2016) Carus Medal (2017) Ron the Kloet Award for Stress Research (2019) Leadership Roles: She is a member of the German National Academy of Sciences (Leopoldina), a Fellow of the American College of Neuropsychopharmacology, and serves on multiple international advisory committees and executive boards in psychiatry and neuroscience.
Professor Richard Wade-Martins is a leading academic in University of Oxford 's Department of Physiology, Anatomy and Genetics . He directs the Molecular Neurodegeneration Research Laboratory and the Oxford Parkinson’s Disease Centre (OPDC). With degrees from Cambridge (MA) and Oxford (DPhil), he has held prestigious fellowships including Wellcome Trust Research Career Development Fellowship and NIH reviewer roles. His research targets molecular mechanisms in Parkinson’s and Alzheimer’s diseases through iPSC models , transgenic mice , and lysosomal function studies . He pioneered work on SNCA , MAPT , and LRRK2 gene pathways. Current projects focus on gene therapy and mitochondrial dysfunction in neurodegeneration. Key publications (2019–2025) reveal trends in single-cell transcriptomics , calcium channel inhibition , and TFEB/TFE3 lysosome modulation . His awards include Wellcome Trust Fellowships and advisory roles for Parkinson's UK , Alzheimer's Research UK , and EU consortia like StemBANCC and EFACTS . He leads the UK Dementia Platform iPSC Initiative and serves on international boards in Luxembourg and Canada.
Robin A. Murphy is a Professor of Experimental Psychology at the University of Oxford and a Fellow and Tutor for Admissions at Corpus Christi College. He holds a PhD from McGill University (Canada) and has contributed over 50 scientific publications on associative learning mechanisms, their role in mental disorders like depression and psychopathy, and translational neuroscientific applications. His research bridges animal and human learning, with a focus on computational psychopathology and neurochemical modulation (e.g., serotonin). Education: Undergraduate degree, Queen's University MA and PhD in Psychology, McGill University Research Interests: Dr. Murphy investigates how associative learning processes underpin mental disorders, particularly through neurochemical systems like serotonin. His work explores causal reasoning biases in depression, psychopathy's learning deficits, and translational models linking animal studies to human cognition. Key themes include agency perception, contingency judgment, and the neural substrates of prejudice. Recent projects involve peptide research in aging and computational modeling of multi-agent systems in depression. Grants and Funding: Supported by MRC, BBSRC, Wellcome Trust, and Japan Society for the Promotion of Science. He has advised UK Research Councils and NSERC (Canada). Labs and Teams: Leads a lab focusing on associative learning mechanisms, collaborating with institutions globally on computational psychopathology and translational neuroscience.
Alicia Che is an Assistant Professor of Psychiatry at Yale University School of Medicine and serves as Director of Graduate Admissions for the Interdepartmental Neuroscience Program. She joined the Yale Department of Psychiatry in 2021 after completing her postdoctoral fellowship with Dr. Natalia De Marco García at Weill Cornell Medical College and Dr. Gord Fishell at NYU. Her research is conducted through the Che Lab at Yale, where she investigates how early life experiences impact brain circuit assembly and mature function in models of psychiatric illness. Yale School of Medicine, Department of Psychiatry Interdepartmental Neuroscience Program Center for Brain & Mind Health Division of Molecular Psychiatry Wu Tsai Institute Yale Center for the Science of Cannabis and Cannabinoids Dr. Che earned her Ph.D. in Physiology and Neurobiology from the University of Connecticut in 2014, where she worked in the laboratory of Dr. Joseph LoTurco. She received her B.S. with triple majors in Biology, Physics, and Physical Chemistry from Pacific Lutheran University in Washington state in 2009. Her research focuses on understanding developmental trajectories following early life experiences to develop diagnostics and early interventions for psychiatric illnesses. Dr. Che's research examines how sensory inputs, social bonding, stress, and substance exposure impact brain development. She employs a multi-dimensional approach to assess transcriptional, circuit, neuronal activity, and behavioral changes across the entire developmental timeline. Her lab currently focuses on four specific areas: the role of oxytocin in social behavior development, circuit dysfunction in PTSD, early-life cannabinoid exposure effects, and the impact of early life stress on development and adulthood. She utilizes advanced techniques including mouse genetics, slice electrophysiology, and longitudinal in vivo 2-photon imaging on behaving animals. Her most recent publications demonstrate significant contributions to understanding neural circuit development, PTSD mechanisms, and the effects of early life experiences on brain function. Her work spans from molecular neuroscience to behavioral outcomes, with publications in top journals including Nature, Neuron, and Nature Communications. Her research has revealed important insights into how translaminar neuronal activity strengthens cortical columns, how oxytocin facilitates social touch development, and how PTSD affects brain transcriptomics. NARSAD Young Investigator Award (2020) K99/R00 Pathway to Independence Award from NINDS (2019) Dr. Che's work has significant implications for understanding and treating neurodevelopmental disorders, PTSD, and the consequences of early life experiences on mental health. She collaborates extensively with researchers across Yale and beyond, with frequent co-authorship with colleagues including Lin Lin, Alex Kwan, and Christopher Pittenger. Her research program bridges basic neuroscience with clinical applications, aiming to translate findings into potential interventions for psychiatric conditions.
Wen Xue is a Professor at UMass Chan Medical School, affiliated with the RNA Therapeutics Institute within the T.H. Chan School of Medicine. She holds multiple additional roles across departments such as the Program in Molecular Medicine, Cancer Biology, and Biochemistry and Molecular Biotechnology at the Morningside Graduate School of Biomedical Sciences. Her research focuses on developing genetic models for liver and lung cancer using CRISPR/Cas9 and RNAi tools. Key areas include CRISPR-mediated genome editing for cancer gene discovery, KRAS inhibition mechanisms, and miRNA networks in lung cancer. She has secured grants from NIH, American Cancer Society, and others. Awards include the NIH Director’s New Innovator Award and Lung Cancer Research Foundation grants. Her lab actively recruits postdoctoral researchers and offers rotation projects in CRISPR technology and cancer biology. Education: B.S. and M.S. in Biochemistry from Nanjing University; Ph.D. in Biochemistry from State University of New York, Stony Brook. Research Interests: Wen Xue’s lab employs CRISPR tools to accelerate cancer gene validation and therapeutic target identification. Projects include: CRISPR-based liver cancer gene correction and oncogene deletion studies. Investigating KRAS inhibition resistance via RNAi and CRISPR in lung cancer models. Characterizing miRNA networks using TCGA data to identify therapeutic miRNA candidates. Her work bridges functional genomics with precision medicine, emphasizing in vivo and in vitro platforms. Publications: Over 100 peer-reviewed articles, including high-impact studies on CRISPR applications in gene therapy and cancer modeling. Recent work explores prime editing, base editing, and viral/non-viral delivery systems for lung diseases. Grants & Awards: NIH grants (P01HL131471, DP2HL137167), American Cancer Society (RSG-16-093), and industry partnerships like the Cystic Fibrosis Foundation. Collaborations include projects on CFTR mutation repair and AAV vector development. Labs/Teams: Xue Lab focuses on cancer genetics and gene editing, with interdisciplinary collaborations in molecular medicine and bioengineering. Ongoing projects aim to translate CRISPR-based therapies into clinical applications.
